Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023890 (
cirrhosis
)
42,195
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Short bowel syndrome
(
SBS
) is associated with changes in the intestinal microbiome and marked local and systemic inflammation. There is also a late complication of
SBS
, intestinal failure associated liver disease (IFALD) in which hepatic steatosis progresses to
cirrhosis
. Most patients with
SBS
arrive at massive intestinal resection after a contaminating intraabdominal catastrophe and have a history of exposure to broad-spectrum antibiotics. We therefore investigated whether the administration of broad-spectrum antibiotics in conjunction with
SBS
in zebrafish (ZF) would replicate these systemic effects observed in humans to identify potentially druggable targets to aid in the management of
SBS
and resulting IFALD. In zebrafish with
SBS
, broad-spectrum antibiotics altered the microbiome, decreased inflammation, and reduced the development of hepatic steatosis. After two weeks of broad-spectrum antibiotics, these fish exhibited decreased alpha diversity, with less variation in microbial community composition between
SBS
and sham fish. Additionally, administration of broad-spectrum antibiotics was associated with decreased expression of intestinal toll-like receptor 4 (
tlr
4), increased expression of the intestinal gene encoding the Farnesoid X receptor (
fxr),
decreased expression of downstream hepatic
cyp7a1
, and decreased development of hepatic steatosis.
SBS
in zebrafish reproducibly results in increased epithelial surface area as occurs in human patients who demonstrate intestinal adaptation, but antibiotic administration in zebrafish with
SBS
reduced these gains with increased cell death in the intervillus pocket that contains stem/progenitor cells. These alternate states in
SBS
zebrafish might direct the development of future human therapies.
NEW & NOTEWORTHY
In a zebrafish model that replicates a common clinical scenario, systemic effects of the administration of broad-spectrum antibiotics in a zebrafish model of
SBS
identified two alternate states that led to the establishment of fat accumulation in the liver or its absence. Broad-spectrum antibiotics given to zebrafish with
SBS
over 2 wk altered the intestinal microbiome, decreased intestinal and hepatic inflammation, and decreased hepatic steatosis.
...
PMID:Broad-spectrum antibiotics alter the microbiome, increase intestinal
fxr
, and decrease hepatic steatosis in zebrafish short bowel syndrome. 3259 9
<< Previous
1
2
3